Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity

The continuous spread of SARS-CoV-2 calls for more direct-acting antiviral agents to combat the highly infectious variants. The main protease (Mpro) is an promising target for anti-SARS-CoV-2 drug design. Here, we report the discovery of potent non-covalent nonpeptide Mpro inhibitors featuring a 1,2,4-trisubstituted piperazine scaffold. We systematically modified the non-covalent hit MCULE5948770040 by structure-based rational design combined with multisite binding and privileged structure assembly strategies. The optimized compound GC-14 inhibits Mpro with high potency (IC50 = 0.40 mu M) and displays excellent antiviral activity (EC50 = 1.1 mu M), being more potent than Remdesivir. Notably, GC-14 exhibits low cytotoxicity (CC50 > 100 mu M) and excellent target selectivity for SARS-CoV-2 Mpro (IC50 > 50 mu M for cathepsins B, F, K, L, and caspase 3). X-ray co-crystal structures prove that the inhibitors occupy multiple subpockets by critical non-covalent interactions. These studies may provide a basis for developing a more efficient and safer therapy for COVID-19.

Automated summary

A potent non-covalent nonpeptide Mpro inhibitor GC-14 has been discovered with high potency against Mpro and excellent antiviral activity, showing low cytotoxicity and excellent target selectivity for SARS-CoV-2 Mpro.